Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the transaction, the insider owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total value of $112,213.98.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Trading Down 5.1%

PHVS traded down $1.57 during trading on Friday, hitting $29.44. The company’s stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. The firm’s 50 day moving average price is $27.62 and its two-hundred day moving average price is $26.03. Pharvaris N.V. has a 12 month low of $14.59 and a 12 month high of $31.14.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Analysts predict that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PHVS has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $42.73.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $1,943,000. Patient Square Capital LP increased its stake in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after buying an additional 101,098 shares during the period. Boothbay Fund Management LLC increased its stake in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock valued at $3,373,000 after buying an additional 118,994 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after buying an additional 23,743 shares during the period. Finally, General Atlantic L.P. increased its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.